Get started
Viking Therapeutics, Inc.Viking Therapeutics, Inc.Viking Therapeutics, Inc.

Viking Therapeutics, Inc.

No trades
OverviewFinancialsNewsCommunityTechnicalsForecastsSeasonalsETFs

Chart


Full chart

Key facts today


Morgan Stanley reduced its price target for Viking Therapeutics (VKTX) to $99, while Raymond James cut its target to $118, emphasizing strong demand for oral GLP-1 therapies.
Analyze the impactAnalyze the impact

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.72 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.71 EUR
Net income (FY)
‪−306.20 M‬ EUR
Revenue (FY)
0.00 EUR
Shares float
‪112.14 M‬
Beta (1Y)
1.05

Employees


Employees (FY)
53
Change (1Y)
+17 +47.22%
Revenue / Employee (1Y)
0.00 EUR
Net income / Employee (1Y)
‪−5.78 M‬ EUR

About Viking Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Brian Lian
Website
vikingtherapeutics.com
Headquarters
San Diego
Founded
2012
IPO date
Apr 29, 2015
Identifiers
3
ISIN US92686J1060
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Check out other big names from the same industry as 1VT.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


XBI
State Street SPDR S&P Biotech ETF
Weight
1.01%
Market value
‪86.99 M‬
USD
VB
Vanguard Small-Cap ETF
Weight
0.05%
Market value
‪85.56 M‬
USD
VBK
Vanguard Small-Cap Growth ETF
Weight
0.12%
Market value
‪48.29 M‬
USD
VXF
Vanguard Extended Market ETF
Weight
0.05%
Market value
‪42.82 M‬
USD
SCHA
Schwab U.S. Small-Cap ETF
Weight
0.08%
Market value
‪16.57 M‬
USD
IWR
iShares Russell Mid-Cap ETF
Weight
0.03%
Market value
‪12.37 M‬
USD
VHT
Vanguard Health Care ETF
Weight
0.05%
Market value
‪11.34 M‬
USD
IWD
iShares Russell 1000 Value ETF
Weight
0.01%
Market value
‪6.64 M‬
USD
IWS
iShares Russell Mid-Cap Value ETF
Weight
0.03%
Market value
‪4.54 M‬
USD
FXH
First Trust Health Care AlphaDEX
Weight
0.36%
Market value
‪3.30 M‬
USD
LABU
Direxion Daily S&P Biotech Bull 3X Shares
Weight
0.56%
Market value
‪3.05 M‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of 1VT is 25.55 EUR — it has decreased by −1.84% in the past 24 hours. Watch Viking Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange Viking Therapeutics, Inc. stocks are traded under the ticker 1VT.
1VT stock has risen by 4.51% compared to the previous week, the month change is a −5.37% fall, over the last year Viking Therapeutics, Inc. has showed a −9.09% decrease.
We've gathered analysts' opinions on Viking Therapeutics, Inc. future price: according to them, 1VT price has a max estimate of 105.31 EUR and a min estimate of 29.49 EUR. Watch 1VT chart and read a more detailed Viking Therapeutics, Inc. stock forecast: see what analysts think of Viking Therapeutics, Inc. and suggest that you do with its stocks.
1VT reached its all-time high on Feb 28, 2024 with the price of 94.32 EUR, and its all-time low was 0.77 EUR and was reached on Aug 3, 2017. View more price dynamics on 1VT chart.
See other stocks reaching their highest and lowest prices.
1VT stock is 3.80% volatile and has beta coefficient of 1.05. Track Viking Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Viking Therapeutics, Inc. there?
Today Viking Therapeutics, Inc. has the market capitalization of ‪2.97 B‬, it has decreased by −1.19% over the last week.
Yes, you can track Viking Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Viking Therapeutics, Inc. is going to release the next earnings report on Apr 29, 2026. Keep track of upcoming events with our Earnings Calendar.
1VT earnings for the last quarter are −1.17 EUR per share, whereas the estimation was −0.76 EUR resulting in a −55.01% surprise. The estimated earnings for the next quarter are −0.84 EUR per share. See more details about Viking Therapeutics, Inc. earnings.
Viking Therapeutics, Inc. revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
1VT net income for the last quarter is ‪−134.24 M‬ EUR, while the quarter before that showed ‪−77.37 M‬ EUR of net income which accounts for −73.50% change. Track more Viking Therapeutics, Inc. financial stats to get the full picture.
No, 1VT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 13, 2026, the company has 53 employees. See our rating of the largest employees — is Viking Therapeutics, Inc. on this list?
Like other stocks, 1VT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Viking Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Viking Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Viking Therapeutics, Inc. stock shows the sell signal. See more of Viking Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.